Effects of sulforaphane on negative symptoms and cognitive impairments in chronic schizophrenia patients: A randomized double-blind trial

IF 3.7 2区医学 Q1 PSYCHIATRY

Journal of psychiatric research Pub Date : 2025-03-13 DOI:10.1016/j.jpsychires.2025.03.023

Haiyu Chen , Jinjun Lu , Tianxiang Zou , Ziwei Teng , Yue Qin , Renrong Wu , Yeliang Yan , Kai Fu , Wenjuan Jiang , Yunxia Ju , Riyong Zhu , Jianzhong Mo , Jian Lu , Jing Huang

{"title":"Effects of sulforaphane on negative symptoms and cognitive impairments in chronic schizophrenia patients: A randomized double-blind trial","authors":"Haiyu Chen , Jinjun Lu , Tianxiang Zou , Ziwei Teng , Yue Qin , Renrong Wu , Yeliang Yan , Kai Fu , Wenjuan Jiang , Yunxia Ju , Riyong Zhu , Jianzhong Mo , Jian Lu , Jing Huang","doi":"10.1016/j.jpsychires.2025.03.023","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The pathological mechanisms of negative symptoms and cognitive impairment in schizophrenia may involve oxidative stress and neuroinflammation. Sulforaphane is an organosulfur compound with antioxidant and anti-inflammatory properties. This study aimed to evaluate its efficacy in ameliorating negative symptoms and cognitive impairments in chronic schizophrenia patients.</div></div><div><h3>Method</h3><div>This 24-week double-blind randomised trial (NCT04521868) recruited schizophrenia patients with significant negative symptoms. Participants were randomly assigned to receive either sulforaphane or placebo and were required to complete at least one post-intervention assessment to evaluate changes in negative symptoms and cognitive functioning. Existing antipsychotic medication treatment regimens remained unchanged throughout the study.</div></div><div><h3>Results</h3><div>A total of 42 patients were included in the statistical analysis, with 28 receiving sulforaphane and 14 assigned to placebo. Sulforaphane significantly reduced the Negative Symptom Score from the PANSS 5-Factor model between groups (<em>p</em> = 0.007) and exhibited a significant time-by-group interaction (<em>p</em> = 0.023), with more pronounced group differences observed after 12 weeks compared to 24 weeks of treatment. Sulforaphane also demonstrated a significant reduction in the original PANSS Negative Symptom Score between groups (<em>p</em> = 0.029). However, sulforaphane showed no significant effects on the MATRICS Consensus Cognitive Battery composite score or its subscores.</div></div><div><h3>Conclusion</h3><div>The significant improvements in the Negative Symptom Score from the PANSS 5-Factor model and the original PANSS Negative Symptom Score in the sulforaphane group suggest the potential of sulforaphane as an adjunctive treatment for ameliorating negative symptoms in chronic schizophrenia. Further research is warranted to explore the effects of sulforaphane on cognitive function.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"184 ","pages":"Pages 464-472"},"PeriodicalIF":3.7000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of psychiatric research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022395625001773","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The pathological mechanisms of negative symptoms and cognitive impairment in schizophrenia may involve oxidative stress and neuroinflammation. Sulforaphane is an organosulfur compound with antioxidant and anti-inflammatory properties. This study aimed to evaluate its efficacy in ameliorating negative symptoms and cognitive impairments in chronic schizophrenia patients.

Method

This 24-week double-blind randomised trial (NCT04521868) recruited schizophrenia patients with significant negative symptoms. Participants were randomly assigned to receive either sulforaphane or placebo and were required to complete at least one post-intervention assessment to evaluate changes in negative symptoms and cognitive functioning. Existing antipsychotic medication treatment regimens remained unchanged throughout the study.

Results

A total of 42 patients were included in the statistical analysis, with 28 receiving sulforaphane and 14 assigned to placebo. Sulforaphane significantly reduced the Negative Symptom Score from the PANSS 5-Factor model between groups (p = 0.007) and exhibited a significant time-by-group interaction (p = 0.023), with more pronounced group differences observed after 12 weeks compared to 24 weeks of treatment. Sulforaphane also demonstrated a significant reduction in the original PANSS Negative Symptom Score between groups (p = 0.029). However, sulforaphane showed no significant effects on the MATRICS Consensus Cognitive Battery composite score or its subscores.

Conclusion

The significant improvements in the Negative Symptom Score from the PANSS 5-Factor model and the original PANSS Negative Symptom Score in the sulforaphane group suggest the potential of sulforaphane as an adjunctive treatment for ameliorating negative symptoms in chronic schizophrenia. Further research is warranted to explore the effects of sulforaphane on cognitive function.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of psychiatric research 医学-精神病学

CiteScore

7.30

自引率

2.10%

发文量

622

审稿时长

130 days

期刊介绍： Founded in 1961 to report on the latest work in psychiatry and cognate disciplines, the Journal of Psychiatric Research is dedicated to innovative and timely studies of four important areas of research: (1) clinical studies of all disciplines relating to psychiatric illness, as well as normal human behaviour, including biochemical, physiological, genetic, environmental, social, psychological and epidemiological factors; (2) basic studies pertaining to psychiatry in such fields as neuropsychopharmacology, neuroendocrinology, electrophysiology, genetics, experimental psychology and epidemiology; (3) the growing application of clinical laboratory techniques in psychiatry, including imagery and spectroscopy of the brain, molecular biology and computer sciences;